- SEK40.57bn
- SEK36.61bn
- SEK2.27bn
Brief: Camurus Says Co And Lilly Enter Collaboration And License Agreement For Long-Acting Fluidcrystal® Incretins
Brief: Camurus Q1 Net Income SEK 197 Million
Brief: Camurus Appoints Anders Vadsholt As CFO
Brief: Camurus: CHMP Recommends Approval Of Oczyesa For Treatment Of Acromegaly In The EU
Brief: Jon Garay Alonso Leaves Position As Camurus CFO
Brief: Camurus Q4 Profit Before Tax Up At Sek 186 Million
Brief: Camurus Expects 2024 Revenues In High End Of SEK 1,810-1,880 Mln Guidance
Oaktree Capital urges UK's Indivior to refresh board (updated)
Brief: Camurus 2024 FY Outlook For Total Revenues Raised To SEK 1,810-1,880 Mln
Brief: Camurus Q3 Net Income SEK 129 Million
US FDA declines to approve Camurus' rare hormone disorder drug
Brief: Camurus AB Says FDA Issues A Crl For Cam2029 Pending FDA's Assessment Of Responses From A Third-Party Manufacturer
British drugmaker Indivior cuts 2024 revenue forecast, shares fall (updated)
Europe Research Roundup: Imperial Brands, Kingfisher, Nestle SA
Brief: Camurus Gains EMA Orphan Drug Status for Octreotide SC Depot
Brief: Senior Executive Fredrik Joabsson Divested SEK 6.8 Mln Worth Of Shares In Camurus
Brief: Camurus Sees Results In Mid To High Range Of 2024 Guidance
Brief: Camurus Q2 Net Income SEK 74 Million
Brief: Camurus: Positive Phase 3 Results From Acroinnova 2 Study Of Octreotide SC Depot (Cam2029) In Acromegaly Patients